Multiple Myeloma

Nizar J. Bahlis, MD, discusses daratumumab (Darzalex) plus lenalidomide (Revlimid) and dexamethasone in newly diagnosed multiple myeloma.

Andrew J. Cowan, MD, discusses efficacy and safety of BCMA CAR T-cell therapy in patients with relapsed/refractory multiple myeloma.

Nina Shah, MD, associate professor of medicine at the University of California, San Francisco (UCSF) Helen Diller Family Comprehensive Cancer Center, discusses daratumumab (Darzalex)-based regimens in the frontline treatment of patients with multiple myeloma.

Thomas G. Martin, MD, discusses the use of selinexor in patients with triple-class refractory multiple myeloma.

Sandy W. Wong, MD, discusses treatments in the pipeline for multiple myeloma.

Peter Voorhees, MD, discusses the updated depth of response data that were reported in the GRIFFIN trial of patients with multiple myeloma.

Nina Shah, MD, discusses newer treatment options in the frontline and maintenance settings in multiple myeloma. 

Sandy Wong, MD, discusses the ongoing research of antibody-drug conjugates in multiple myeloma.

The European Commission has granted marketing authorization for daratumumab in combination with bortezomib, thalidomide, and dexamethasone for the treatment of patients with newly diagnosed multiple myeloma who are eligible for autologous stem cell transplant.

Larry Anderson, MD, PhD, discusses recent FDA approvals in multiple myeloma.

The FDA has granted a priority review designation to a biologics license application for belantamab mafodotin as a treatment for patients with relapsed/refractory multiple myeloma who received prior therapy with an immunomodulatory drug, a proteasome inhibitor, and an anti-CD38 antibody.

Thomas G. Martin, MD, discusses the current treatment approaches in multiple myeloma, as well as the agents that are generating excitement in relapsed/refractory patient populations.